News Headlines Article

Gilead hepatitis C drug combo lands promise of quick FDA review
San Francisco Business Times

Gilead Sciences Inc. should hear within six months whether regulators approve a drug combination that can be taken orally to defeat hepatitis C. The Foster City-based drug developer (NASDAQ: GILD), whose research operations are led by Chief Scientific Officer Norbert Bischofberger, said Monday that the Food and Drug Administration has granted priority review of the company’s new drug application for a once-daily combination of already-approved Sovaldi and experimental ledipasvir.